| Product NDC: | 43595-080 |
| Proprietary Name: | Oleptro |
| Non Proprietary Name: | Trazodone Hydrochloride |
| Active Ingredient(s): | 150 mg/1 & nbsp; Trazodone Hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 43595-080 |
| Labeler Name: | Labopharm Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022411 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20100202 |
| Package NDC: | 43595-080-03 |
| Package Description: | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (43595-080-03) |
| NDC Code | 43595-080-03 |
| Proprietary Name | Oleptro |
| Package Description | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (43595-080-03) |
| Product NDC | 43595-080 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Trazodone Hydrochloride |
| Dosage Form Name | TABLET, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20100202 |
| Marketing Category Name | NDA |
| Labeler Name | Labopharm Inc. |
| Substance Name | TRAZODONE HYDROCHLORIDE |
| Strength Number | 150 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Serotonin Reuptake Inhibitor [EPC] |